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ABSTRACT - Purpose. P-glycoprotein (Pgp) is a member of the ABC-transporter family that transports 
substances across cellular membranes acting as an efflux pump extruding drugs out of the cells.  Pgp plays a 
key role on the pharmacokinetics of several drugs. Herein, we have studied the effects of 
immunosuppressants on Pgp function, assessing rhodamine-123 (Rho123) uptake and efflux in different T-
cell subsets. Methods. Different immunosuppressants such as Cyclosporine (CsA), Rapamycin (Rapa) and 
Tacrolimus (Tac) were used to assess the in vitro effect on Pgp function of main T-cell subsets among 
healthy volunteers. We measured Rho123 uptake, efflux and kinetic of extrusion in CD4+ and CD8+ subsets 
by flow cytometry. Antigen-specific memory T-cell responses were assessed by measuring T-cell 
proliferation and cytokine secretion using an allogeneic mixed lymphocyte reaction. Results. Rho123 uptake 
in groups treated with CsA and CsA+Rapa was significantly decreased compared to non-treated group and 
the other immunosupressants in both T cells subsets. Pgp activity was also reduced in CsA and CsA+Rapa 
compared to the other immunosupressants but it was only significant in the CsA group for CD8+ subset.  
Kinetic extrusion of Rho123 by Pgp in all groups was faster in CD8+ T cells. All immunosuppressants and 
the specific Pgp inhibitor PSC833 diminished antigen-primed T-cell proliferation, especially CD8+ T-cell 
subset. Conclusions. Our data indicate that small molecules immunosuppressants, especially CsA, inhibit 
Pgp activity and T-cell function being the CD8+ T cells more susceptible to this effect. These findings 
support the importance of Pgp when designing combined immunosuppressive regimens. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________________________ 
 
INTRODUCTION  
  
The MDR1 gene product P-glycoprotein (Pgp) is 
the most studied membrane protein of the large 
mammalian ABC transporter family (1). These 
plasma membrane proteins play a major role in 
determining drug uptake, distribution and 
excretion processes, and they play a key role in 
drug pharmacokinetics (2). Pgp has been 
described as a possible mediator to explain 
variability in toxicity patterns associated with 
immunosuppressive therapies (3). There is an 
increasing interest in the precise role of Pgp in T 
lymphocyte activation and antigen presenting cell 
function. Pgp actively extrudes a wide variety of 
structurally diverse cytotoxic compounds out of 
the cell. It is widely expressed in the epithelial 
cells of the kidney, liver and intestine, and in the 
endothelial cells of brain and placenta (4). Also, 
its expression has been described in lymphoid cell 
populations from human bone marrow and 
peripheral blood (5). Specifically, it has been 
shown on the membrane of pluripotent stem cells, 
monocytes, dendritic cells, CD4+ and CD8+ T 
lymphocytes, NK cells, and B lymphocytes, 
suggesting that Pgp may influence cell-mediated 
immune responses (6-9). 
ABC transporters may be therapeutic targets 
in organ transplantation, but the importance of 
Pgp in immune function still remains unclear (10-
13). Up-regulation of Pgp in T-cell populations 
could result in decreasing intracellular drug 
concentrations rendering these cells resistant to 
immunosuppressive therapy despite appropriate 
plasma drug exposure (14). 
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Pgp and cytochrome P450 3A4 (CYP3A4) are 
determinants of the bioavailability of widely used 
immunosuppressants such as cyclosporine A 
(CsA), tacrolimus (FK506/Tac) and sirolimus 
(Rapa) (15). These immunosuppressants 
themselves, as substrates and/or inhibitors of Pgp, 
could alter the bioavailability of many 
concomitantly drugs being potentially important 
in drug interactions (16,17). CsA, remains as an 
important immunosuppressive drug in solid organ 
transplantation and has been described as a potent 
Pgp inhibitor (18). Conversely, the role of Tac 
and Rapa on Pgp function still remains undefined. 
Tac is 10-100 times more potent than CsA as an 
immunosuppressive agent (19) with effective 
concentrations of 0.003-0.019µM compared to 
0.083-0.208 µM for CsA (20, 21). Rapa is 
structurally similar to Tac that modulates the 
immune response at a different level to 
calcineurin inhibitors (CNIs). The combination of 
CNIs, either CsA or Tac, with mTOR inhibitor 
(mTORi) exert a potent immunosuppressive 
effect, but potentiates CNI-related nephrotoxicity 
(18, 22).  
In a previous study (23) we investigated the 
impact of the association of Rapa with Tac or 
CsA on Pgp expression in a rat nephrotoxicity 
model, showing a renal over-expression related to 
CsA exposition. The aim of the current study was 
to evaluate the effect of several CNIs and mTORi 
on Pgp function evaluated by Rho123 uptake and 
efflux measurements in CD4+ and CD8+ T-cell 
subsets. 
Therefore, CsA in monotherapy and 
associated with Rapa decreases Pgp activity in 
CD8+ T-cells. Immunosuppressive drugs and Pgp 
inhibitor significantly reduced the CD8+ T-cell 
proliferation and cytokine release. The Pgp 
inhibition could be a novel therapeutic target to 
avoid allograft rejection in solid organ 
transplantation. 
 
MATERIAL AND METHODS 
 
Reagents and antibodies 
The following monoclonal antibodies were used 
to characterize cell subpopulations: mouse anti-
human CD4-APC, mouse anti-human CD3-APC 
and mouse anti-human CD8-PE were purchased 
from eBioscience (San Diego, CA, USA). 
PSC833 was kindly provided by Novartis (Basel, 
Switzerland). FK506 (Tacrolimus) was a gift from 
Astellas Pharma Inc. Cyclosporine and rapamycin 
were purchased from Sigma-Aldrich (Madrid, 
Spain) as 7-Aminoactinomycin D (7-AAD). 
Appropriate stock solutions of drugs were 
prepared in culture medium RPMI 1640 
(Biological Industries, Israel) and diluted in 100% 
dehydrated ethanol. Phosphate Buffered Saline 
(PBS) was obtained from PAA (Cambridge, UK). 
Biotarget-1 is a specific culture medium for 
lymphocytes which was used; it was purchased 
from Biological Industries. Rho123 was 
purchased from Invitrogen, Molecular Probes 
Inc., USA as 5,6-carboxyfluorescein diacetate 
succinimidyl ester (CFSE). Cytometric Bead 
Array (CBA) Human Th1/Th2/Th17 kit was 
purchased from BD.Biosciences Pharmingen (San 
Diego, CA). 
 
Isolation of peripheral blood lymphocytes   
Peripheral blood mononuclear cells (PBMCs) 
were isolated from healthy volunteers (n=8) by 
Ficoll-Paque Plus (GE Healthcare Bio Sciences 
AB, Uppsala, Sweden) density gradient 
centrifugation according to the manufacturer’s 
instructions. Cells were then washed and 
resuspended in Biotarget-1 medium supplemented 
with 1% L-Glutamine, 1% Sodium Pyruvate and 
1% Pen-Streptomycin. Cell viability was 
confirmed by trypan blue exclusion and was 
always greater than 90%. Lymphocytes were 
frozen in freezing medium as described 
previously (24).  
The study groups were defined according to 
the different immunosuppressive drugs used: 
cyclosporine (CsA 2.5µM), rapamycin (Rapa 
0.25µM), tacrolimus (Tac 0.1µM) and two more 
groups with Rapa associated with CNIs. A non-
stimulated, non-treated (negative control) and 
non-treated stimulated (positive control) were 
added (n=8 for group). Stimulated cells are 
exposed to allogeneic T-cell depleted 
lymphocytes. Drug concentrations were obtained 
from Pawarode et al. choosing those in the upper 
level (25). 
Informed consent was signed from each 
healthy volunteer after the nature and possible 
consequences of the study were fully explained. 
Written informed consent was obtained in 
accordance with the Hospital Universitari de 
Bellvitge Ethic Committee.  
 
Flow cytometry analysis  
Flow cytometry was performed on a 
FACSCalibur flow cytometer (Becton, Dickinson 
and Company, BD) with four-color analysis. The 
four optical filters on the FACS Calibur were Fl 1 
at 530±15 nm (for Rho123 uptake), Fl 2 at 585nm 
(for CD8-PE), Fl 3 at 670 nm (for 7-AAD) and Fl 
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4 at 660 nm (for CD4-APC). Acquisition was 
stopped when 10,000 gated events were collected 
in the fluorescence cell count histogram. Gating 
was based on forward scatter and side scatter dot 
plots by encircling populations with amorphous 
regions and then excluding dead cells (life gate) 
by 7-ADD counterstaining (under dye-
compatibility conditions). We monitored the 
linearity of the flow cytometer measurements 
daily to show the results in accurate standard 
fluorescence units by using calibration standard 
beads (K0110, Dako, Glostrup, Denmark) to 
decrease the variation in flow results and to 
provide the reference dye fluorescence for 
quantitative measurements. These quantitative 
measurements included mean fluorescence 
intensity (MFI) in linear values, which were 
transformed, according to the manufacturer's 
instructions, into calibrated values of molecules of 
equivalent soluble fluorochrome (MESF). A 
manual calibration curve (log  = a × log  + b) was 
constructed to convert fluorescence measurements 
to MESF units. Data were analyzed using Cell 
Quest software. 
 
Measurement of Pgp function by flow 
cytometry 
Pgp function was estimated using three 
parameters: 1) considering that ABC transporters 
such as ABCB1 may handle not only the efflux 
but also the influx of their substrates, the 
intracellular uptake of Rho123 was the first 
evaluated; 2) Cells pump out Rho123 by passive 
diffusion through Pgp (26), so Rho123 efflux 
assays were used to evaluate Pgp activity; and 3) 
The time needed to efflux 50% of Rho123 out the 
cells (t50; average rate of drug efflux) was used to 
define the efflux kinetic parameter (Fig. 1). 
 
Intracellular Rho123 uptake 
The intracellular Rho123 uptake was established 
after 30 min of co-incubation of cells with 
Rho123. Human PBMCs (1x106 cells) were 
suspended in 1ml of supplemented Biotarget-1 
and incubated o/n at 37ºC 5%CO2 with the 
different immunosuppressive drugs. Finally, cells 
were washed with PBS and resuspended in 1mL 
Biotarget-1. To allow Rho123 uptake, cell 
suspension was incubated with Rho123 at a final 
concentration of 200ng/mL for 30 min at 37ºC 
5%CO2, avoiding light exposure, in the presence 
or absence of PSC833 (10µM). PSC833 was used 
as a Pgp-specific competitive inhibitor to estimate 
the amount of Rho123 accumulated after Pgp 
inhibition. At the end of the uptake period, cells 
were kept on ice to stop Pgp activity and then 
washed with ice-cold PBS without Ca2+ and Mg2+ 
to remove extra cellular Rho123. PSC833 was 
also maintained during the washes to avoid 
periods of non-inhibition. 
 
 
 
 
 
Figure 1. Pgp function measured by flow cytometry. 1) Intracellular Rho123 uptake (30 min). 2) Pgp activity (Rho123 
uptake) was measured after the first 30 min. 3) Kinetic profile of Rho123 extrusion (t50; average rate of drug efflux) was 
evaluated at different time points (0, 30, 60, 90 and 120 min) according to each immunosuppressive treatment.  
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After washing, 0.5x106 cells of each treatment 
were stained for phenotypic expression of surface 
CD4+ and CD8+. After 20 min incubation on ice, 
cells were washed with PBS supplemented with 
2% Fetal Bovine Serum and immediately 
acquired on the flow cytometer. The remaining 
half of the cells was resuspended in 1ml 
Biotarget-1 without Rho123 to allow efflux of the 
dye out of the cell, for 120 min at 37ºC 5%CO2. 
At the end of the efflux incubation, cells were 
kept on ice to prevent further reaction and stained 
for phenotypic expression of surface CD4+ and 
CD8+ and then immediately acquired on the 
cytometer. To detect cells with membrane damage 
(necrotic cells) 7-AAD was added to all samples 
and incubated for 15 min on ice, avoiding light 
exposure prior to flow cytometry analysis in order 
to exclude dead cells from the analysis.  
 
Determination of Pgp activity 
Basal Pgp activity was estimated by Rho123 
fluorescence at 30 min after an established 
loading period considered enough time to achieve 
the intracellular steady-state level but not so long 
as to induce de novo activity (27). In our 
experiments, Pgp activity was estimated on the 
kinetic of Rho123 uptake and extrusion using 
Rho123 fluorescence (MESF units). 
 
Kinetic of Rho123 extrusion 
Different time points (0, 30, 60, 90 and 120 min) 
were chosen to evaluate the early, the linear and 
the late phases of the efflux for CD4+ and CD8+ 
T-cell subsets. For kinetic measurements we 
calculated the time needed to efflux 50% of 
Rho123 out of cells (t50; average rate of drug 
efflux). 
 
Antigen-specific memory  T-cell proliferation 
assay by flow cytometry 
To asses the effect of the different 
immunosupressive agents and the specific Pgp 
inhibitor (PSC833) on memory/effector T-cell 
responses an alloantigen-specific memory T-cell 
co-culture was done. For this purpose a short term 
antigen-specific memory T-cell line was produced 
by mixing 2x105 PBMC from a responder subject 
with 2x105 stimulator T-cell depleted (Rosette 
Sep Human CD3 Depletion Cocktail Kit; Stem 
Cell Technologies, Grenoble, France) and 
irradiated (40 Gy) PBMCs obtained from an 
allogeneic subject. Cells were incubated in a final 
volume of 200µL in a complete medium consisted 
of RPMI-1640 supplemented with 10% heat-
inactivated FBS, 1% L-Glutamine and 1% Pen-
Streptomycin in  round-bottom 96-well cell 
culture plates (Costar, Cambridge, MA). The 
plates were then placed in a humidified 37ºC, 
5%CO2 incubator for 6 days. Then, cells were 
harvested and incubated o/n with the different 
immunosuppressants and PSC833 at the same 
concentrations than Pgp function assay. 2x105 of 
the resulting primed responder PBMCs for each 
treatment were labeled with succinimidyl ester of 
carboxyfluorescein diacetate (CFSE 5µM) as 
described (28) and were plated again in duplicate 
wells with the same stimulator cells in a ratio of 
1:1 for 5 days in the same conditions. Culture 
supernatants were harvested after this period of 
time, snap frozen and stored at -80ºC until 
analysis. As positive responder control, PBMCs 
were stimulated with 1 µg/ml phytohemagglutinin 
(PHA). Proliferation of responder cells was 
evaluated by FACS analysis of T-cells subsets  
using monoclonal antibodies specific for CD3, 
CD4 and CD8. Experiments are representative of 
four independent assay. 
 
Cell cytokine analysis by Flow Cytometry 
Cytokine secretion into supernatants by PBMCs 
was analyzed by flow cytometry with a 
fluorescent bead assay (CBA Human 
Th1/Th2/Th17 kit) after staining according to the 
manufacturer’s instructions. Cytokines 
quantification was performed on non-treated 
stimulated and treated with immunosuppressants 
and the specific Pgp inhibitor (PSC833) in 
PBMCs after MLR. Experiments are 
representative of three independent assays. 
 
STATISTICAL ANALYSIS 
 
All data are presented as mean±SE. Group means 
were compared with analysis of variance 
(ANOVA) for parametric values, followed by 
post hoc Fisher’s test. All p-values were two-
tailed and a p-value of less than 0.05 was 
considered statistically significant. 
 
RESULTS 
 
Intracellular Rho123 uptake of CD4+ and 
CD8+ T-cell subsets 
Intracellular Rho123 uptake in CsA groups (CsA 
and CsA+Rapa) was significantly decreased 
compared to non-treated group and the other 
immunosupressants in CD4+ and CD8+ T cells. 
Considering the intracellular Rho123 uptake after 
30 minutes of incubation as the baseline 
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intracellular value, CD8+ T cells showed higher 
Rho123 uptake than CD4+ (Fig. 2).  
 
Pgp activity of CD4+ and CD8+ T-cell subsets  
The study of the kinetics of Rho123 extrusion in 
T-cell population displayed a noticeable slower 
efflux in CsA and CsA+Rapa compared to the 
others immunosupressants at 60, 90 and 120 
minutes (p<0.001). In contrast, macrolides-treated 
T cells showed a similar extrusion speed to the 
non-treated group (Fig. 3). 
Thereafter, we further analysed the kinetic 
pattern of Rho123 efflux on CD4+ and CD8+ T-
cell subsets. As shown in figure 4, CD4+ T cells 
displayed slower extrusion rate than CD8+ T cells, 
showing a similar kinetic than Rho 123 uptake. 
After two hours of efflux, there was still more 
than 50% of the Rho123 in the CD4+ T cells, 
whereas in CD8+ T cells 70-80% of Rho123 had 
already been extruded. In both T-cell subsets 
additional treatments with PSC833 increased 
fluorescence (data not shown) corroborating the 
role of Pgp on T cells. Normalized values of 
Rho123 extrusion at different time-points 
expressed in percentages are depicted in table 1. 
We observed significant differences in 
Rho123 extrusion between non-treated group and 
CsA alone and CsA+Rapa for CD8 T-cell subset. 
On the other hand, in CD8 T cells, Pgp activity in 
CsA group was significantly lower than 
macrolides alone and associated groups 
(Rapa,Tac and Tac+Rapa). In CD4+ T cells, CsA 
groups showed less Pgp function compared with 
all groups but no significant differences were 
found between any group (Fig. 5). 
Pgp activity calculated as t50 (average rate of 
drug efflux) on CD4+ and CD8+ T-cell subsets 
displayed a similar kinetic pattern than Pgp 
activity measured by Rho123 extrusion. Rho123 
t50 corroborated faster efflux time in CD8+ subset 
than in CD4+ (Fig. 6).  Both CD4+ and CD8+ T 
cells showed longer time to efflux 50% of the 
drug in the CsA groups (alone and associated with 
Rapa) than the other treatments and the non-
treated group confirming the inhibitory effect of 
CsA. 
 
 
 
 
Figure 2. Intracellular Rho123 uptake by flow cytometry analysis in CD4+ and CD8+ subsets. Human PBMCs (1x106 
cells) were pre-incubated at 37ºC 5%CO2 o/n with the different immunosuppressive drugs, and Rho123 uptake was 
measured after 30 min of co-incubation of cells with Rho123. Values are means (MESF)±SE. N=8 different subjects 
for each group.  
 
J Pharm Pharmaceut Sci (www.cspsCanada.org) 15(3) 407 - 419, 2012 
 
 
 
412 
Table 1. Rho123 fluorescence in CD8+/CD4+ T cells from each immunosuppressive group after 30, 60, 90 and 120 
minutes efflux in comparison with minute 0 (100%). The results are presented as normalized values. Data are in 
percentage as mean±SE. Each experiment was performed from blood of healthy volunteers. N=8 different subjects for 
each group. 
 
 
 
Figure 3. T-cell population kinetic profile. Drug-efflux curves were obtained after Rho123 uptake. Cells were 
incubated for up to 120 min at 37ºC 5%CO2. Kinetic profile of Rho123 extrusion was evaluated using different time 
points (0, 30, 60, 90 and 120 min) according to each immunosuppressive treatment. Arbitrary fluorescence units were 
transformed to calibrated MESF values and normalized (*p<0.001). 
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Figure 4. Representative histograms of the kinetic profile of Rho123 extrusion in CD4+ and CD8+ subsets. Ten 
thousand events of PBMCs were acquired for each assay. N=8 different subjects for each subsets and 
immunosuppressants groups. 
 
 
Antigen-specific memory T-cell proliferation 
 
Pgp blockade using the specific inhibitor PSC833 
showed a similar inhibition profile on lymphocyte 
proliferation as all the immunosupressants (Fig. 
7). Proliferation of antigen-specific memory CD3+ 
T cells was significantly abbrogated in groups 
treated with PSC833 and immunosuppressants 
compared to non-treated groups (5-15% vs 30% 
of T-cell proliferation respectively,  p<0.05). All 
immunosupressants in monotherapy  inhibited T-
cell proliferation in a similar degree as PSC833. 
Interestingly, both associations with Rapa 
(CsA+Rapa and Tac+Rapa) showed a further 
proliferation reduction compared with these 
immunosupressants in monotherapy. 
 
J Pharm Pharmaceut Sci (www.cspsCanada.org) 15(3) 407 - 419, 2012 
 
 
 
414 
 
Figure 5. Pgp activity by flow cytometry analysis measured with MESF units of Rho123 fluorescence in CD4+ and 
CD8+ T-cell subsets. N=8 different subjects for each group. Any difference was observed among treatment groups in 
CD4+ T-cell subset. 
 
 
 
Figure 6. Pgp kinetic profile (t50; average rate of drug efflux) by flow cytometry analysis in CD4+ and CD8+ T-cell 
subsets. Arbitrary fluorescence units were transformed to calibrated MESF values. N=8 different subjects for each 
group.  
J Pharm Pharmaceut Sci (www.cspsCanada.org) 15(3) 407 - 419, 2012 
 
 
 
415 
In CD4+ and CD8+ T-cell subsets all 
immunosuppressant therapies and  PSC833 
diminished lymphocyte proliferation, and this 
effect was especially more evident in CD8 than 
CD4 T cells (25% vs 15% of T-cell proliferation 
inhibition respectively,  p<0.05).  However, 
despite T-cell proliferation decreased in PSC833 
group in CD4 and CD8 T cells, there was only 
significant difference for CD8. Furthermore, in 
the CD4+ subset, both associations with Rapa 
showed a reduced proliferation compared with 
these immunosupressants in monotherapy, in a 
similar pattern as CD3 T cells, but in this case 
only Tac+Rapa achieved statistical differences 
(p<0.05).  
 
Cytokine secretion in MLR  
Th1 pro-inflammatory cytokines such as IFN-γ 
and TNF-α, were significantly reduced in all 
immunosuppressive therapies and PSC833-treated 
groups than in those non-treated (p<0.05). 
However, CsA group did not reach statistical 
significance in the IFN-γ secretion, even it was 
significantly higher than all the other 
immunosuppressants and PSC833 (p<0.05). On 
the other hand, only Tac showed significantly 
lower TNF-α release compared to the other 
treatment groups (p<0.05) (Fig. 8). Regarding the 
Th2 cytokine profile, PSC833 and the 
immunosuppressive therapies, except for CsA, 
diminished IL-6 secretion compared to the non-
treated stimulated group. Furthermore, the two 
macrolides in monotheray showed a significant 
decrease compared with both drugs associated 
(p<0.05). Concerning IL-10, rapamycin groups 
showed an important decrease in this cytokine 
secretion compared with the other groups, 
reflecting that Rapa plays an important role in the 
modulation of IL-10 (Fig. 8).  
 
 
 
 
Figure 7.  Antigen-specific memory T-cell proliferation under different immunosupressants and Pgp specific inhibitor 
(PSC833) in different T-cell subsets. Values are means (MESF)±SE. Experiments are representative of four 
independent assay.  
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Figure 8. Cell cytokine analysis by flow cytometry into supernatants by PBMCs in MLR. Fluorescent bead assay 
(CBA Human Th1/Th2/Th17 kit). Experiments are representative of three independent assays.  
 
 
DISCUSSION 
 
Pgp is a functionally active efflux pump 
physiologically expressed in several tissues and 
peripheral blood mononuclear cells. Its role in 
pumping drugs out of the cells is widely known 
but its function in immunologic mechanisms is 
complex and still not fully understood. The 
crucial role of ABC transporters in lymphocyte 
survival and antigen presenting cell differentiation 
has been described (13). Pendse et al underlined 
the important immunoregulatory effects of P-
glycoprotein-inhibiting agents, suggesting a 
promising novel Pgp therapeutic target for 
immune modulation in acute and chronic allograft 
rejection, and cell-mediated autoimmune 
disorders (29). 
In our study, we analyzed the influence of 
immunosuppressive drugs on intracellular 
Rho123 uptake and the kinetic profile of Pgp 
activity in different lymphocyte subsets. 
Immunosuppressive agents are Pgp substrates 
and/or inhibitors that may influence the functional 
response of T cells (30). Our results demonstrated 
a significant decrease in Rho123 uptake in  T 
lymphocyte subsets treated with CsA, suggesting 
the role of Pgp not only in the efflux but also in 
the influx of Pgp substrates inside the cells. In 
addition, our results illustrate the inhibitory effect 
of CsA in blocking Pgp function not only in the 
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efflux but also in the influx of Pgp substrates. On 
the other hand, Pgp activity in T cells treated with 
both macrolides showed a similar profile to cells 
without immunosuppressive drugs; therefore, at 
the concentrations used, Rapa and Tac did not 
modify Pgp activity. 
When the efflux of Rho123 was analyzed, T 
cells treated with CsA with or without Rapa 
presented a slower kinetic profile compared to 
Tac and Rapa alone or associated, confirming the 
potent inhibitory effect of CsA on Pgp compared 
to the other immunosuppressors. Cells treated 
with CsA spent 2-fold minutes to efflux 50% of 
the Rho123 as compared to the macrolide groups. 
Furthermore, the time required to extrude Rho123 
was longer in T cells incubated with CsA plus 
Rapa than CsA alone, suggesting an additive 
inhibitory effect of rapamycin on Pgp when 
combined with CsA. The  association, Tac and 
Rapa, and both immunosupressants separately, 
lasted the same time to efflux 50% of the Rho123 
as took the non-treated non-stimulated group. In 
fact, rapamycin and tacrolimus affected Pgp 
activity but they did not modulate Pgp function at 
pre-established doses. Similarly to what was 
previously reported by Pawarode and collegues 
(25) here, we show that CsA seems to be a broad-
spectrum MDR modulator impairing drug 
transport at the clinically achievable concentration 
of 2.5 µM, tacrolimus enhanced cellular drug 
uptake at 1 µM, but not at its clinically achievable 
concentration (0.1 µM). Rapamycin exerts the 
optimal effect of enhancing cellular drug uptake 
at 2.5 µM, but it was not effective at its clinically 
achievable concentration of 0.25 µM. 
The specific role of Pgp modulators and their 
kinetic profile is thus essential to fully 
characterize and approach the broad properties of 
immunosuppressive drugs (31), Laurent G et al 
(32) and Gupta et al (33) clearly showed that the 
expression of Pgp was higher in CD4+ than in 
CD8+ T cells. Functionally, Pgp was more 
efficient in the CD8+ subpopulation. In our study 
we found higher Rho123 uptake and efflux in 
CD8+ T cells than in CD4+ T cells, suggesting that 
both influx and efflux of Pgp substrates showed a 
different modulation depending on the T-cell 
subset studied. Furthermore and, in line with 
previously published results (33), the kinetic of 
Rho123 extrusion was also remarkebly faster in 
CD8+ than in CD4+ subsets suggesting a 
physiologic role of Pgp within the cytotoxic T 
lymphocyte subset. Pgp function was modified 
after T-cell pre-tretament with 
immunosuppressors showing slower Rho 
extrussion in  both CsA groups compared with 
macrolide groups. The Pgp kinetic was also faster 
in CD8+ T cells than CD4+ T cells.  
Nowadays the interest of the role of ABC 
transporters is increasing. Their extruding 
function and/or their inhibitory functions could be 
an interesting new pharmacodynamic target. 
Recently, Brennan et al examined a new molecule 
(LIM-0705) designed to activate specific ABC 
transporters in the kidney and liver, facilitating 
the export of Tac out of vulnerable cells in order 
to reduce toxicity while preserving its 
immunosuppressive effect. The increase in the 
intra-lymphocyte drug concentration is associated 
with more effective inhibition of lymphocyte 
proliferation by CsA in vitro, these results could 
translate in vivo into more effective protection 
against graft rejection (34). Upon secondary 
exposure to alloantigen, both CD4+ and CD8+ 
memory T cells rapidly proliferate and 
differentiate into effector cells. It is well known, 
that CNIs are the most robust drugs to suppress 
alloreactive effector/memory T cells (35). 
Therefore, we studied whether both Pgp blocker 
and the different immunosuppressants showed an 
efficient inhibitory effect on alloreactive memory 
T cells. Our results proved that Pgp blockade and 
immmunosuppressants resulted mainly in CD8+ 
lymphocyte inhibition diminishing lymphocyte 
proliferation as CD3+ subset. In contrast in CD4+ 
T-cell proliferation was slightly inhibited by 
PSC833 and all immunosuppressants. 
Considering that antigen-specific memory T cells 
have less sensibility to classical 
immunosuppressive agents being the main 
responsible of acute cellular rejection episodes 
after transplantation these results have relevance 
in clinical renal transplantation. 
Based on its known function as a 
transmembrane transporter (36), Pgp has been 
proposed to facilitate the membrane transport 
and/or release of cytokines. In our study we 
measured cytokine secretion in MLR with 
different immunosuppressants and specific Pgp 
inhibitor. Our data showed that pro-inflammatory 
Th1 cytokines secretion, IFN-γ and TNF-α, were 
significantly reduced in all treatment groups, 
pointing up the maximum response after Tac 
exposition. On the other hand, Th2 cytokine 
response by IL-6 was minimized in all 
immunosupressants except for CsA and PSC833 
compared with non-treated stimulated group. On 
the other hand, rapamycin in monotherapy or 
associated was the only immunosupressant able to 
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reduce IL-10 secretion, reflecting the important 
role of Rapa in IL-10 modulation. 
In summary, Pgp activity appears to be 
modulated depending on the immunosupressor 
treatment with faster Pgp kinetic in CD8+ than 
CD4+ T-cell subsets. Our data indicate that CsA 
inhibit Pgp activity and T-cell function being the 
CD8+ T cells more susceptible to this effect than 
CD4+ T cells. On the other hand, 
immunosuppressants significantly reduced T-cell 
proliferation of CD4+ and CD8+ subsets. Our 
results underline the importance of the 
immunoregulatory effects of Pgp in T-cell 
activation and in immunosuppressive regimens. 
Thus, looking for new strategies to target this T-
cell subset population is necessary to further delve 
into potential mechanisms of Pgp in T-cell 
activation. The inhibition of this protein could be 
a novel therapeutic target in order to avoid 
allograft rejection in solid organ transplantation.  
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